⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNDX News
Syndax Pharmaceuticals, Inc.
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
globenewswire.com
SNDX
Form 8-K
sec.gov
SNDX
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
globenewswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
globenewswire.com
SNDX
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
globenewswire.com
SNDX
Form 8-K
sec.gov
SNDX
Form 8-K
sec.gov
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
globenewswire.com
SNDX